"There is significant data and broad physician support that suggests ELVR using the Emphasys EBV can be effective but that patient selection and valve placement are the critical factors in improving the probability of success of the therapy," added Dr. Rodney Perkins, Founder and Chairman of Pulmonx. "We believe that the combined platform offering of the Emphasys EBV and the Chartis System will strengthen the ability of physicians to transform the treatment of emphysema for millions of patients worldwide and support expanded usage of this therapy."
Pulmonx's newly expanded product portfolio will be unveiled at the Pulmonx booth (1205) at ATS 2009, the International Conference of the American Thoracic Society, beginning May 15th in San Diego, Calif. Researchers also will present new data for the first time on ELVR using the combination of the Emphasys EBV and Chartis System. The poster presentation is scheduled for 1:30-4:00 p.m. Wednesday, May 20, 2009, in Room 16 A-B at the San Diego Convention Center.
"Emphasys was a true pioneer in EBV therapy, and we have gained tremendous institutional knowledge through the acquisition," said Richard Ferrari, Managing Partner of De Novo Ventures, an investor in Pulmonx. "A number of factors, including the addition of the Chartis System with the Emphasys EBV, will support commercial adoption of the product worldwide. We are hopeful that our efforts will allow us to move forward and fulfill the critical unmet medical need for a minimally invasive option that improves the quality of life for patients living with severe emphysema."
|SOURCE Pulmonx Corporation|
Copyright©2009 PR Newswire.
All rights reserved